The Safety of Intracameral Moxifloxacin Injection for Endophthalmitis Prophylaxis after Phacoemulsification
Intracameral Moxifloxacin Injection for Endophthalmitis Prophylaxis
Keywords:
endophthalmitis, intracameral injection, moxifloxacin, phacoemulsificationAbstract
Acute endophthalmitis after cataract surgery is rare but results in severe permanent visual loss. There are many studies on the efficiency of intracameral 0.5% moxifloxacin to post-cataract surgery endophthalmitis prophylaxis. The aim of this study was to evaluate the safety of undiluted intracameral 0.5% moxifloxacin for endophthalmitis prophylaxis after phacoemulsification. This study was a prospective randomized controlled clinical trial by studying data between June, 2019 and December, 2019. Ninety patients, 100 eyes were randomized into two groups, 50 eyes were treated with intracameral 0.5% moxifloxacin (500 mug/0.1 ml) after phacoemulsification and 50 eyes were undergone phacoemulsification without intracameral injection. Best corrected visual acuity, intraocular pressure, central corneal thickness, endothelial cell counts and central macular thickness were evaluated preoperatively and for six weeks postoperatively. There were not statistically significant in baseline preoperatively characteristics between two groups including age, sex, site, BCVA, IOP, CCT, endothelial cell counts and CMT. At six weeks postoperatively, there were not statistically significant in BCVA, IOP, CCT, endothelial cell counts and CMT. There were no toxic anterior segment syndrome and endophthalmitis occurred. In conclusion, the intracameral of 0.5% moxifloxacinis safe to be used through the final step after phacoemulsification
References
2. Miller JJ, Scott IU, Flynn HW, Smiddy WE, Newton J, Miller D. Acue onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual outcomes after treatment. Am J Ophthalmol 2005;139(6):983-7.
3. Endophthalmitis Vitrectomy Study Group. Results of the endophthalmitis vitrectomy study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113(12):1479-96.
4. ESCRS Endophthalmitis Study Group. Prophylaxis of postoperative endophthalmitis following cataract surgery: result of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 2007;33(6):978-88.
5. Delyfer M-N, Rougier M-B, Leoni S, Zhang Q, Dalbon F, Colin J, et al. Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery. J Cataract Refract Surg 2001;37(2):271-8.
6. Espiritu CR, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 2007;33(1):63-8.
7. Matsuura K, Miyoshi T, Suto C, Akura J, Inoue Y. Efficacy and safety of prophylactic intracameral moxifloxacin injection in Japan. J Cataract Refract Surg 2013;39(11):1702-6.
8. Koktekir BE, Aslan BS. Safety of prophylactic intracameral moxifloxacin use in cataract surgery. J Ocul Phamacol 2012;28(3):278-82.
9. Lane SS, Osher RH, Masket S, Belani S. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J Cataract Refract Surg 2008;34(9):1451-59.
10. Arbisser LB. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. J Cataract Refract Surg 2008;34(7):1114-20.
11. Gardner SK. Ocular drug penetration and pharmacokinetic principles. In: Lamberts DW, Potter DE, editors, Clinical ophthalmic pharmacology. Boston, Massachusetts State, USA: Little, Brown and Company; 1987. p.1-52.
12. Stroman DW, Dajcs JJ, Cupp GA, Schlech BA. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol 2005;50(11):S16-31.
13. O'Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg 2007;33(10):1790-800.
14. Andrew XZ, Wyatt BM, Steven S, Ambati BK. Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery. Int Ophthalmol 2006;36(4):493-8.
15. Mamalis N. TASS associated with intracameral antibiotic injection [Internet]. 2013 [cited 2013 Sept 27]. Available from:URL:http://www.arcrs.org/Press-Releases
